COMP <GO>
NEOG vs CLDX // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Neogen Corporation (NASDAQ) VS. Celldex Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: NEOG 7
— CLDX 3
■ METRIC PARITY
LAST: $12.26 (+1.16%) • MKT CAP: $2.68B
options-implied-move
—
LAST: $29.89 (+0.78%) • MKT CAP: $2.35B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NEOG VS. CLDX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NEOG | CLDX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 46.90% | 87.10% | -40.20 | CLDX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -0.60% | -35.00% | +34.40 | NEOG | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 3.11% | -9.10% | +12.21 | NEOG | /fcf-yield <GO> |
| Operating Margin | -2.50% | -60.00% | +57.50 | NEOG | /operating-margins <GO> |
| Net Profit Margin | -0.90% | -60.00% | +59.10 | NEOG | /net-margins <GO> |
| Revenue Growth (YoY) | -2.70% | -65.00% | +62.30 | NEOG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.45 | 20.25 | -18.80 | CLDX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 3/9 | +4.00 | NEOG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.3 | 45.5 | -0.20 | CLDX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.68B | $2.35B | $329.2M | NEOG | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NEOG REV | CLDX REV | NEOG GROSS % | CLDX GROSS % | NEOG FCF | CLDX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $870.4M | $1.5M | 46.9% | 87.1% | $83.2M | -$213.7M |
| FY 2024 | $894.7M | $7.0M | 47.1% | 97.2% | $58.2M | -$159.7M |
| FY 2023 | $924.2M | $6.9M | — | — | $35.3M | -$107.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NEOG // BETA —
CLDX // BETA —